Christina T. Loguidice

During a recent OncLive Peer Exchange®, a panel of CRC experts discussed the heterogeneity of metastatic CRC and the need to identify patient subsets within this disease to enable a precision medicine approach.

Investigators have achieved some success with immune checkpoint inhibitors and antiangiogenesis agents in patients with advanced gastroesophageal cancers, and exciting new agents targeting different tumor growth pathways are under investigation.

During an OncLive Peer Exchange®, a panel of experts on multiple myeloma discussed new agents and combinations that are improving the care of patients with relapsed multiple myeloma and reviewed strategies for treating these patients when they develop drug resistance.

Although soft-tissue sarcoma is seldom diagnosed in adults, the development of several new therapies in recent years for patients with rare subtypes is energizing leaders in the field and underscoring the need for a multidisciplinary approach to care.

More patients than ever before may now be good candidates for adjuvant therapy and derive long-term benefits from it, but new data and expanding treatment options have led to many new questions on how to optimize treatment for melanoma.

A panel of experts during an OncLive PeerExchange® provided practical definitions for biochemical recurrent hormone-naïve nonmetastatic, metastatic hormone-naïve advancing, nonmetastatic castration-resistant, and metastatic castration-resistant prostate cancer.

During an OncLive Peer Exchange® a panel of AML experts discussed these newly approved agents and provided insight on how they are rapidly changing the standard of care for various AML subgroups.

A panel of experts discuss the latest data on several novel agents for ALL and provided insights on how to align these treatments in challenging settings.

Experts offer their perspectives on developments in the field of chronic lymphocytic leukemia, such as novel combinations and emerging agents.

In an OncLive Peer Exchange® discussion, experts in breast malignancies reviewed some exciting new developments in TNBC.

In the three years since the FDA launched its breakthrough therapy program, the designation has become a coveted status for emerging agents as biopharmaceutical companies scramble to make their mark in an increasing competitive environment.

A combination of cytoreductive surgical resection and hyperthermic intraperitoneal chemotherapy-sometimes referred to as "hot chemotherapy bath"-has the potential to provide some patients with long-term survival.

Inhibiting EZH2 may improve outcomes in patients with clear cell ovarian carcinoma who harbor a ARID1A mutation.

Historically, most cancer treatments have been administered in oncology offices or hospitals, but oral medications are becoming increasingly common, and oral formulations of chemotherapy, targeted therapies, and hormonal therapies are available.

The Ancient Indians were the fi rst to use pens around 5000 BCE. While these writing implements were primitive, typically consisting of hollowed out reeds that could hold a small amount of ink, which was generally soot in water with a plant gum binder, they were used for thousands of years and are still used today in certain parts of Pakistan.

Radon is an invisible, odorless, and tasteless radioactive gas that is released into the air or dissolves into groundwater as uranium in rocks or soil decays.

Radiation therapy has been used to treat cancer for more than 100 years, and was made possible by the discovery of X-rays in 1895 by German physicist Wilhelm Conrad Röntgen, which allowed tumors to be detected more easily and noninvasively.

Chemotherapy-induced nausea and vomiting (CINV) is one of the most common and most feared side effects of chemotherapy.

The concept of personalized medicine is not new. As doctor Ogan Gurel points out in an article published in 2007 on WTN News, personalized medicine has been practiced since ancient times in the form of surgery.

Twitter really only wants to know one thing: "What are you doing?"